Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Current Assets (2017 - 2025)

Historic Current Assets for Denali Therapeutics (DNLI) over the last 9 years, with Q3 2025 value amounting to $882.6 million.

  • Denali Therapeutics' Current Assets rose 158.36% to $882.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $882.6 million, marking a year-over-year increase of 158.36%. This contributed to the annual value of $864.4 million for FY2024, which is 1876.65% down from last year.
  • Latest data reveals that Denali Therapeutics reported Current Assets of $882.6 million as of Q3 2025, which was up 158.36% from $934.7 million recorded in Q2 2025.
  • In the past 5 years, Denali Therapeutics' Current Assets registered a high of $1.4 billion during Q1 2021, and its lowest value of $864.4 million during Q4 2024.
  • In the last 5 years, Denali Therapeutics' Current Assets had a median value of $1.1 billion in 2021 and averaged $1.1 billion.
  • Within the past 5 years, the most significant YoY rise in Denali Therapeutics' Current Assets was 13985.04% (2021), while the steepest drop was 4001.06% (2021).
  • Denali Therapeutics' Current Assets (Quarter) stood at $897.2 million in 2021, then skyrocketed by 52.95% to $1.4 billion in 2022, then fell by 22.46% to $1.1 billion in 2023, then decreased by 18.77% to $864.4 million in 2024, then increased by 2.1% to $882.6 million in 2025.
  • Its Current Assets was $882.6 million in Q3 2025, compared to $934.7 million in Q2 2025 and $878.6 million in Q1 2025.